A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for Treatment of Leber's Hereditary Optic Neuropathy

Inclusion Criteria: * Adults ≥18 and ≤ 50 years old at the time of loss of vision in the second eye. * Able to provide informed consent and willing to comply with all study visits and examinations * Diagnosis of LHON based on clinical and ophthalmic functional/anatomic test findings, and satisfactory documentation of the mitochondrial DNA mutation m.11778G\>A * Loss of vision in both eyes of ≥1 year and ≤10 years at the time of the Screening Visit and current clinically stable visual function (as assessed by the Investigator) * Able to self-administer eye drops as demonstrated at screening or having a care provider who can do so * Documentation of having satisfactorily completed at least two previous Humphrey automated visual field tests prior to screening. * Women of childbearing potential must agree to use birth control as specified in the protocol from the date they sign the informed consent form Exclusion Criteria: * Any other ocular pathology requiring treatment with prescription topical ophthalmic drops (e.g., glaucoma, dry eye) * Cup to disc ratio of \> 0.8 in either eye * Media opacity, suboptimal pupillary dilatation, or refractive error that interferes with adequate retinal imaging * Known to be immunocompromised or receiving systemic immunosuppression * Any disease or medical condition that in the opinion of the Investigator would prevent the subject from participating in the study or might confound study results * Participation in other investigational drug or …